

Volume 44 Number 9 September 2021

IJAO

The International Journal of Artificial Organs

Organ and tissue replacement: from bench to bedside

**Abstracts submitted to 47th ESAO
Congress, Virtual in London
7-11 September, 2021**

Uniting scientific minds towards
lasting artificial organs



Official Journal of the European Society for Artificial Organs



Editor in Chief

Andrea Remuzzi, Bergamo, Italy

ESAO editor

Thomas Groth, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

Founding editor

Diego Brancaccio, NephroCare, Milan, Italy

Honorary editor

Claudio Ronco, International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy

Coordinating editors

Diego Brancaccio, NephroCare, Milan, Italy

George Dunea, University of Illinois, Chicago, USA

Tofy Mussivand, University of Ottawa Heart Institute, Ottawa, Canada

Akiba Takashi, Tokyo Women's Medical University, Tokyo, Japan

Section editors

Apheresis, dialysis and liver support

Joachim Jankowski, Uniklinik RWTH Aachen, Aachen, Germany

Antonio Santoro, Policlinico Sant'Orsola-Malpighi, Bologna, Italy

Cardiac assist devices and artificial heart

Steven Jacobs, UZ Leuven, Leuven, Belgium

Aldo Domenico Milano, Ospedale Borgo Trento, Italy

Artificial lung, ECMO and respiratory support

Khosrow Mottaghy, Uniklinik RWTH Aachen, Aachen, Germany

Filip De Somer, Ghent University, Gent, Belgium

Sensory organs and neural stimulation

Manfred Bijak, Medical University of Vienna, Vienna, Austria

Tissue engineering, bioartificial organs and regenerative medicine

Manuela Raimondi, Politecnico di Milano, Milan, Italy

Dimitrios Stamatialis, University of Twente, Enschede, The Netherlands

Biomaterials and nanotechnology

John Hunt, University of Liverpool, Liverpool, UK

Personalized medicine and individualized care

Harald Mischak, Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany

Mechanical prostheses, robotics and medical technology

Marcel Rutten, TU/e University of Technology, The Netherlands

Editorial board

Stephen R. Ash, Ash Access Technology, Inc., Lafayette (LA), USA

Stephen F. Badylak, University of Pittsburgh Medical Center, Pittsburgh (KS), USA

Andrea Buscaroli, Ospedale Santa Maria delle Croci, Ravenna, Italy

Kenneth M.C. Cheung, University of Hong Kong, Hong Kong, China

Zhanfeng Cui, Oxford University, Oxford, UK

Peter Czermak, University of Applied Sciences Mittelhessen, Giessen, Germany

Angel L. De Francisco, Universidad de Cantabria, Santander, Spain

Alicia J. El Haj, Keele University, Stoke-on-Trent, UK

Fabrizio Fabrizi, Maggiore Hospital and IRCCS Foundation, Milan, Italy

Joerg C. Gerlach, University of Pittsburgh Medical Center, Pittsburgh (KS), USA

Birgit Glasmacher, Leibniz Universität Hannover, Hannover, Germany

Jonathan Himmelfarb, University of Washington, Portland (OR), USA

Nicholas A. Hoenich, Newcastle University, Newcastle-upon-Tyne, UK

Robin Hughes, King's College London, London, UK

Ulrich Kertzscher, Charité Universitätsmedizin Berlin, Berlin, Germany

Ingrid Ledebo, Gambro Corporate Research, Lund, Sweden

Edward F. Leonard, Colombia University, New York (NY), USA

Mona Marei, Alexandria University, Alexandria, Egypt

Ivan Martin, University Hospital Basel, Basel, Switzerland

Bart Meyns, University Hospitals Leuven, Leuven, Belgium

Marco Morra, Nobil Bio Ricerche, Portacomaro, Italy

Gerhard Rakhorst, University Medical Center of Groningen, Groningen, The Netherlands

Rui Reis, University of Minho, Guimarães, Portugal

Giuseppe Remuzzi, Mario Negri Institute, Bergamo, Italy

Igor Sauer, Charité Universitätsmedizin Berlin, Berlin, Germany

Heinrich Schima, Medical University of Vienna, Vienna, Austria

Aleksandar Sikole, University Clinic of Nephrology, Skopje, Republic of Macedonia

Shimon Slavin, International Center for Cell Therapy & Cancer Immunotherapy, Tel Aviv, Israel

Marco Somaschini, Bolognini Hospital, Lugano-Sorengo, Switzerland

Sergio Stefoni, S. Orsola University Hospital, Bologna, Italy

Hirofumi Tanaka, Kobe University Graduate School of Medicine, Yokohama, Japan

Visith Thongboonkerd, Mahidol University, Bangkok, Thailand

Raymond Vanholder, University Hospital Ghent, Ghent, Belgium

Nosratola D. Vaziri, University of California Irvine, Irvine (CA), USA

Bart Verkerke, University of Groningen, Groningen, The Netherlands

Beat von Albertini, Centre De Dialyse Cecil, Lausanne, Switzerland

Gordana Vunjak-Novakovic, University of Colombia, New York (NY), USA

Beat Walpoth, University Hospital Bern, Geneva, Switzerland

Carmine Zoccali, Azienda Ospedaliera Bianchi Melacchino Morelli, Reggio Calabria, Italy

Joseph Zwischenberger, University of Kentucky, Lexington (KY), USA

Editorial office

Silvia Nalli, Editorial Assistant

Subscriptions

The *International Journal of Artificial Organs* (ISSN: 0391-3988, print; 1724-6040, online) is published monthly by SAGE Publications Ltd (London, Thousand Oaks, CA, New Delhi, Singapore, Washington DC and Melbourne), 1 Oliver's Yard, 55 City Road, London EC1Y 1SP, UK.

Annual subscription (2021) including postage: Combined Institutional Rate (print and electronic) £1,183/US\$2,187. Electronic only and print only subscriptions are available for institutions at a discounted rate. Note VAT is applicable at the appropriate local rate. Visit sagepublishing.com for more details including individual rates, single-copy rates and pay per view. Abstracts, tables of contents and contents alerts are available online free of charge for all. Further details are available from SAGE Publications Ltd, 1 Oliver's Yard, 55 City Road, London EC1Y 1SP, UK, tel: +44 (0)20 7324 8500, email: subscriptions@sagepub.co.uk, and in North America, SAGE Publications Inc, PO Box 5096, Thousand Oaks, CA 91320, USA.



SAGE is a member of CrossRef.

© SAGE Publications Ltd, 2021.

All rights reserved. No portion of the contents may be reproduced in any form without written permission from the publisher. SAGE Publishing is a trading name of SAGE Publications Ltd, Registered in England No.1017514.

Apart from fair dealing for the purposes of research or private study, or criticism or review, and only as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the Publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency or your equivalent national blanket licensing agency. Enquiries concerning reproduction outside those terms should be sent to SAGE.

Disclaimer: The authors, editors, and publisher will not accept any legal responsibility for any errors or omissions that may be made in this publication. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Abstracting and indexing

Please visit journals.sagepub.com/home/iao and click on the 'More' button (under about this journal), then click the Abstracting/Indexing tab to view a full list of databases in which this journal is indexed.

Printed in UK.

Six weeks' advance notice must be given when notifying of change of address. Please visit us at addressupdates.sagepub.com/support/tickets/new and complete the SAGE Journals Address Updates form. If you get your printed copy through your society membership, please contact them directly.

¹Université de technologie de Compiègne (UTC), Compiègne, France,

²Université Sidi Mohamed Ben Abdellah (USMBA), Fès, Morocco,

³Polyclinique Saint-Côme, Compiègne, France.

Objectives: Water's scarcity is a major problem even in Europe with climate changes. Hemodialysis is a treatment with a high economic and ecological impact, especially regarding water consumption. The reject from the reverse osmosis (RO) system of the water treatment loop is about 250 L/dialysis session. This mildly salted water is usually wasted. The aim of this work is to evaluate the desalination of RO rejects by electrodialysis, to promote its re-use.

Methods: A 2³ full factorial design was applied to desalination of a model solution (NaCl, conductivity of 2 mS/cm) to study the effects of flow rate (Q), initial feed concentration (C) and applied voltage (E) on the demineralization rate and specific energy consumption (SPC).

Results: Optimal conditions (E and Q) for desalination were established with the model solution. The same operating conditions were applied to desalinate RO rejects with total dissolved salts (TDS) circa 1.3 g/L. Reducing conductivity of RO rejects from 1.96 mS/cm to 0.1 mS/cm was obtained with a low SPC (1.37 Wh L⁻¹). The process efficacy was also evaluated by ionic flux transport and current efficiency.

Discussion: Electrodialysis can satisfy a high demineralization rate with low energy consumption. The duration of the treatment depends on the conductivity target.

Conclusion: Treatment of RO rejects is feasible with electrodialysis. The process can be adapted upon the standards for irrigation or sterilization.

Acknowledgements: This study was partially supported by ITE from Alliance Sorbonne Université (IDEX SUPER).

K5- COMPARISON OF DIFFERENT HOLLOW FIBRE HAEMODIALYSIS MODULE CONFIGURATIONS BY A CFD MULTISCALE APPROACH

Cancilla N¹, Gurreri L¹, Marotta G², Ciofalo M¹, Cipollina A¹, Tamburini A¹, Micale G¹

¹Dipartimento di Ingegneria, Università degli Studi di Palermo, Viale delle Scienze Ed. 6, 90128 Palermo, Italy, ²Medtronic, Via Camurana 1, 41037 Mirandola, Modena, Italy.

Objectives: The study aims to predict 3-D flow and solute concentrations fields both for blood and dialysate and overall performance parameters (such as dialysate pressure drop and clearance) for different hollow-fibre haemodialysis modules.

Methods: A multiscale approach was used. At small (unit cell)-scale, dialysate flow and mass transfer around straight cylindrical fibres arranged in regular lattices were simulated. At module-scale, hydraulic permeabilities and mass transfer coefficients derived from small-scale simulations were used to define two different porous media representative of blood and dialysate, sharing the same volume and exchanging solute. Simulations involved different module configurations, sharing the same membrane area but differing in geometry and inlet-outlet arrangement. Literature values of solute diffusive permeability for commercial PES membranes were used.

Results and discussions: For given blood and dialysate flow rates (300 and 450 mL/min, respectively), different module configurations yielded very different dialysate-side flow patterns and pressure drops, moderately different Sherwood numbers but similar values of the clearance. For urea, this ranged between 209 and 235 mL/min in most configurations, indicating that almost all the membrane area was active in most configurations. For a typical commercial geometry, the predicted

clearances at different blood flow rates exhibited a satisfactory agreement with experimental measurements (maximum discrepancy <2%).

Conclusions: Using commercial membranes properties, dialysate-side mass transfer resistance is small compared with blood-side and membrane contributions. As membranes with higher diffusive permeability will be developed, the influence of dialysate-side resistance will become larger and an accurate prediction of the dialysate flow field will become more important.

K6- HOW μ CT-SCANNING PROVIDES US WITH A VALIDATED PORTFOLIO OF HAEMODIALYSERS WHEN DECREASED ANTICOAGULATION IS NEEDED

Vanommelaeghe F¹, Josipovic I², Boone M², Van Biesen W¹, Elloot S¹

¹Nephrology department, Ghent University Hospital, Gent, Belgium,

²Centre for X-ray Tomography, Physics and Astronomy, Ghent University, Gent, Belgium.

Objectives: While systemic anticoagulation is most widely used in haemodialysis (HD), contraindications to its use might occur in particular settings. In this case, membranes with heparin grafting or with improved biocompatibility claim their suitability. To quantify the performance of different dialysers with decreased anticoagulation, fiber blocking was assessed by micro-computed tomography (μ CT).

Methods: Different cross-over designs included ten maintenance HD patients being dialysed at midweek using either Evodial 1.3 (Baxter), FX800 (Fresenius Medical Care), or Solacea™ 19H (Nipro) in different dialysis modes, i.e. pre and post-dilution haemodiafiltration (pre-HDF, post-HDF), and HD. Anticoagulation was given as half the regular dose (1/2), quarter (1/4) or without anticoagulation (zero). Dialyser fiber blocking was quantified in the dialyser outlet potting using a 3D μ CT scanning technique.

Results: The percentage open fibres post-dialysis (i.e. >70% fiber surface area) was for HD with 1/2 anticoagulation lower in FX800 than in Solacea™ (95[74;98] versus 100[99;100]), and for HD with zero anticoagulation 80[77;89] for Solacea™ and 95[65;98] for Evodial. From 1/4 to zero anticoagulation in Solacea™, fiber patency was decreased for pre-HDF and HD, i.e. from 96[87;99] to 76[61;85] with pre-HDF and from 99[97;99] to 80[77;89] with HD. Comparing the results for zero anticoagulation, post-HDF (i.e. 94[82;97]) performed as good as HD and pre-HDF.

Conclusion: Beside the heparin-grafted Evodial dialyser, the biocompatible Solacea™ dialyser provides promising results for use in conditions where systemic anticoagulation is contraindicated. Surprisingly, pre-HDF, although diluting the blood, was not more effective for fiber patency in case of zero anticoagulation than post-HDF and HD.

K7- A KINETICS BASED ALGORITHM TO TREAT ACUTE NEONATAL HYPERAMMONAEMIA

Snauwaert E¹, De Rudder J², Verloo P¹, Dhont E¹, Raes A¹, Van Biesen W², Elloot S²

¹Department of Pediatrics, Ghent University Hospital, Gent, Belgium,

²Department of Nephrology, Ghent University Hospital, Gent, Belgium.

Objectives: Acute neonatal hyperammonaemia is associated with poor neurological outcomes and high mortality. Kinetic modelling was performed to develop an algorithm to achieve a fast decline in serum ammonia.

Methods: Four hyperammonemic patients underwent 11 haemodialysis sessions, i.e. 5 with the 4008/FXPaed (Fresenius Medical Care), and 6